Improvement in insulin sensitivity and prevention of high fat diet-induced liver pathology using a CXCR2 antagonist.
AZD5069
NAFLD
NASH
Neutrophils
Type 2 diabetes
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
12 07 2022
12 07 2022
Historique:
received:
16
02
2022
accepted:
28
05
2022
entrez:
13
7
2022
pubmed:
14
7
2022
medline:
16
7
2022
Statut:
epublish
Résumé
Liver pathology (LP) characteristic of non-alcoholic fatty acid disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is a prevalent co-morbidity of type 2 diabetes (T2D). Accumulating evidence indicates that neutrophils driving insulin resistance (IR), including hepatic IR, precipitate T2D-associated NAFLD/NASH. We hypothesized that targeting neutrophil accumulation into insulin-sensitive tissues in mice using a CXCR2 antagonist under T2D-precipitating high fat diet (HFD) could improve insulin sensitivity and prevent the progression towards liver pathology reminiscent of NAFLD/NASH. Mice were age-matched and on standard rodent chow prior to 1:1 randomization into control and HFD formulated with the CXCR2 antagonist AZD5069 or with biologically inactive substitute. They were monitored for metabolic changes including insulin sensitivity using the hyperinsulinemic-euglycemic clamp and hepatic histopathologic evaluation in H&E-stained sections as well as via immunofluorescence microscopy of liver sections for leukocyte markers, collagen 1A1 formation, α-smooth muscle actin (SMA), and galectin-3 expression, for 16 weeks. Statistical tests used to determine significant differences among study groups and outcomes include Student's t-test, one-way ANOVA, repeated measures two-way ANOVA, and Fisher's exact test, depending on the analytical question. Compared to mice on HFD, mice in the AZD5069-formulated HFD exhibited improved insulin sensitivity, a modest reduction in weight gain, and a significant improvement in LP and markers related to NAFLD/NASH. Mice in the AZD5069-formulated HFD also exhibited reduced neutrophil accumulation into the liver at the end of the 16 week study period. These results show, for the first time, the effectiveness of a selective CXCR2 antagonist to improve insulin sensitivity, concomitantly preventing the progression towards LP characteristic of NAFLD/NASH. This represents a novel approach to target IR and developing LP under T2D-susceptible conditions using a single agent. Furthermore, our data extend the growing evidence in support of neutrophils as a leukocyte population that imprints and maintains a chronic inflammatory state in the progression of dysregulated metabolism in liver-specific co-morbid conditions.
Sections du résumé
BACKGROUND
Liver pathology (LP) characteristic of non-alcoholic fatty acid disease (NAFLD)/non-alcoholic steatohepatitis (NASH) is a prevalent co-morbidity of type 2 diabetes (T2D). Accumulating evidence indicates that neutrophils driving insulin resistance (IR), including hepatic IR, precipitate T2D-associated NAFLD/NASH. We hypothesized that targeting neutrophil accumulation into insulin-sensitive tissues in mice using a CXCR2 antagonist under T2D-precipitating high fat diet (HFD) could improve insulin sensitivity and prevent the progression towards liver pathology reminiscent of NAFLD/NASH.
METHODS
Mice were age-matched and on standard rodent chow prior to 1:1 randomization into control and HFD formulated with the CXCR2 antagonist AZD5069 or with biologically inactive substitute. They were monitored for metabolic changes including insulin sensitivity using the hyperinsulinemic-euglycemic clamp and hepatic histopathologic evaluation in H&E-stained sections as well as via immunofluorescence microscopy of liver sections for leukocyte markers, collagen 1A1 formation, α-smooth muscle actin (SMA), and galectin-3 expression, for 16 weeks. Statistical tests used to determine significant differences among study groups and outcomes include Student's t-test, one-way ANOVA, repeated measures two-way ANOVA, and Fisher's exact test, depending on the analytical question.
RESULTS
Compared to mice on HFD, mice in the AZD5069-formulated HFD exhibited improved insulin sensitivity, a modest reduction in weight gain, and a significant improvement in LP and markers related to NAFLD/NASH. Mice in the AZD5069-formulated HFD also exhibited reduced neutrophil accumulation into the liver at the end of the 16 week study period.
CONCLUSIONS
These results show, for the first time, the effectiveness of a selective CXCR2 antagonist to improve insulin sensitivity, concomitantly preventing the progression towards LP characteristic of NAFLD/NASH. This represents a novel approach to target IR and developing LP under T2D-susceptible conditions using a single agent. Furthermore, our data extend the growing evidence in support of neutrophils as a leukocyte population that imprints and maintains a chronic inflammatory state in the progression of dysregulated metabolism in liver-specific co-morbid conditions.
Identifiants
pubmed: 35831885
doi: 10.1186/s12933-022-01564-y
pii: 10.1186/s12933-022-01564-y
pmc: PMC9277870
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
130Informations de copyright
© 2022. The Author(s).
Références
Diabetes. 2006 Feb;55(2):390-7
pubmed: 16443772
Hepatology. 2010 Sep;52(3):913-24
pubmed: 20648476
Am J Pathol. 2022 Jan;192(1):31-42
pubmed: 34710382
J Biol Chem. 2007 Apr 20;282(16):11658-66
pubmed: 17197447
Eur J Immunol. 2015 Sep;45(9):2446-56
pubmed: 26220361
Eur J Biochem. 1998 Jul 1;255(1):67-73
pubmed: 9692902
Nat Med. 2012 Sep;18(9):1407-12
pubmed: 22863787
J Pathol. 2015 Sep;237(1):85-97
pubmed: 25950520
Lab Anim Res. 2018 Dec;34(4):133-139
pubmed: 30671098
Endocrine. 2017 Jul;57(1):72-82
pubmed: 28508193
Am J Physiol Endocrinol Metab. 2019 Dec 1;317(6):E1205-E1217
pubmed: 31573846
J Endocrinol Invest. 2018 May;41(5):509-521
pubmed: 29189999
JAMA Netw Open. 2019 Oct 2;2(10):e1912565
pubmed: 31584681
Thromb Haemost. 2013 Mar;109(3):399-406
pubmed: 23364297
Front Cell Dev Biol. 2018 Nov 12;6:150
pubmed: 30483502
Int J Mol Sci. 2021 Jun 25;22(13):
pubmed: 34202257
J Endocrinol. 2014 Aug;222(2):267-76
pubmed: 24928936
Nutrients. 2019 Jul 05;11(7):
pubmed: 31284400
Curr Opin Hematol. 2014 Jan;21(1):8-15
pubmed: 24275691
J Inflamm (Lond). 2009 Aug 27;6:25
pubmed: 19709445
Cells. 2019 Mar 08;8(3):
pubmed: 30857223
Drugs R D. 2018 Jun;18(2):149-159
pubmed: 29856004
J Clin Transl Hepatol. 2021 Feb 28;9(1):40-50
pubmed: 33604254
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
Biochemistry. 1997 Mar 4;36(9):2716-23
pubmed: 9054580
Diabetes Metab Syndr. 2016 Apr-Jun;10(2 Suppl 1):S77-81
pubmed: 26810159
Biochim Biophys Acta. 2014 Mar;1842(3):446-62
pubmed: 23707515
Diabetes. 2005 Dec;54 Suppl 2:S11-7
pubmed: 16306328
J Biol Chem. 1994 Nov 25;269(47):29355-8
pubmed: 7961909
Clin Appl Thromb Hemost. 2014 Mar;20(2):159-63
pubmed: 22992349
Immunity. 2019 Feb 19;50(2):378-389.e5
pubmed: 30784579
J Innate Immun. 2013;5(4):304-14
pubmed: 23571274
J Clin Endocrinol Metab. 2014 Jun;99(6):1983-92
pubmed: 24712577
Front Physiol. 2018 Feb 20;9:113
pubmed: 29515456
J Clin Invest. 2016 Jan;126(1):12-22
pubmed: 26727229
Cell Metab. 2009 Apr;9(4):339-49
pubmed: 19356715
J Clin Invest. 2004 Jul;114(2):147-52
pubmed: 15254578
J Am Assoc Lab Anim Sci. 2017 Jan 1;56(1):95-97
pubmed: 28905722
World J Gastroenterol. 2019 Sep 7;25(33):4904-4920
pubmed: 31543682
Cytokine. 2005 Jul 7;31(1):9-17
pubmed: 15967374
Biomedicines. 2021 Apr 21;9(5):
pubmed: 33919366
Ann Hepatol. 2020 Jul - Aug;19(4):359-366
pubmed: 32349939
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1799-808
pubmed: 22723441
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):32-42
pubmed: 27729660
Nagoya J Med Sci. 2020 Aug;82(3):391-397
pubmed: 33132423
Exp Mol Pathol. 2015 Aug;99(1):155-62
pubmed: 26112094
Mol Immunol. 2006 Mar;43(7):897-914
pubmed: 16084593
Gastroenterology. 2020 May;158(6):1611-1625.e12
pubmed: 32027911
J Hepatol. 2019 Oct;71(4):793-801
pubmed: 31279902
Front Immunol. 2020 Jun 24;11:1169
pubmed: 32670278
J Innate Immun. 2022;14(1):4-30
pubmed: 33849008
Circ Res. 2020 May 22;126(11):1590-1612
pubmed: 32437300
Int J Mol Sci. 2018 Jan 26;19(2):
pubmed: 29373564
Biol Rev Camb Philos Soc. 2016 May;91(2):452-68
pubmed: 25740151
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1618-1624
pubmed: 30060948
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2673-2674.e3
pubmed: 33157318
Lancet Respir Med. 2016 Oct;4(10):797-806
pubmed: 27574788
J Diabetes Complications. 2014 Mar-Apr;28(2):226-33
pubmed: 24342268
Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):145-159
pubmed: 30482910
J Clin Invest. 2006 Jul;116(7):1793-801
pubmed: 16823477
PLoS One. 2018 Dec 11;13(12):e0208634
pubmed: 30533032
Hepatology. 2019 Nov;70(5):1841-1855
pubmed: 31034092
Ann Nutr Metab. 2015;67(4):218-27
pubmed: 26452040
Eur J Immunol. 1998 Jan;28(1):164-70
pubmed: 9485196
J Hepatol. 2019 Nov;71(5):1012-1021
pubmed: 31301321
Int J Obes (Lond). 2006 Sep;30(9):1347-55
pubmed: 16534530
Mol Cell Endocrinol. 2019 Aug 1;493:110480
pubmed: 31176759
Hepatology. 2018 Apr;67(4):1204-1206
pubmed: 29091293
Am J Physiol Gastrointest Liver Physiol. 2011 Nov;301(5):G825-34
pubmed: 21836057
Cells. 2021 Sep 06;10(9):
pubmed: 34571976
J Hepatol. 2022 Mar;76(3):526-535
pubmed: 34710482
PLoS One. 2015 Mar 10;10(3):e0120092
pubmed: 25756662
Eur Med J Hepatol. 2018;6(1):100-109
pubmed: 29930864
J Biol Chem. 2009 Jul 31;284(31):20692-8
pubmed: 19494115
BMC Gastroenterol. 2020 Jul 6;20(1):210
pubmed: 32631250
J Clin Invest. 2011 Jun;121(6):2111-7
pubmed: 21633179
Scand J Immunol. 2020 Nov;92(5):e12971
pubmed: 32892401
Mol Immunol. 1993 Mar;30(4):359-67
pubmed: 8384312
Am J Physiol. 1985 Mar;248(3 Pt 1):E353-62
pubmed: 3883806
QJM. 2012 May;105(5):425-32
pubmed: 22156706
FEBS J. 2022 Jun;289(11):3024-3057
pubmed: 33860630
Expert Opin Ther Targets. 2016;20(5):615-26
pubmed: 26609894